Valuation: Nectar Lifesciences Limited

Market Cap 180.66Cr 1.9Cr 1.65Cr 1.54Cr 1.41Cr 2.66Cr 2.7Cr 18Cr 7.08Cr 90Cr 7.12Cr 6.97Cr 300.44Cr P/E 2024
137x
P/E 2025 -4.53x
Enterprise Value 742.93Cr 7.8Cr 6.77Cr 6.34Cr 5.8Cr 11Cr 11Cr 74Cr 29Cr 371.19Cr 29Cr 29Cr 1.24TCr EV / Sales 2024
0.77x
EV / Sales 2025 0.64x
Free-Float
44.34%
Yield 2024 *
-
Yield 2025 -
11/07 Nectar Lifesciences Limited Announces Change in Registered Office Address CI
30/05 Nectar Lifesciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
06/03 Nectar Lifesciences Limited completed the acquisition of Avensis Exports Private Limited. CI
02/03 Nectar Lifesciences to acquire 100% paid-up equity share capital of Avensis Exports RE
02/03 Nectar Lifesciences Limited agreed to acquire Avensis Exports Private Limited for INR 2.5 million. CI
23/01 Nectar Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
15/01 Tranche Update on Nectar Lifesciences Limited's Equity Buyback Plan announced on December 3, 2025. CI
06/01 Nectar Lifesciences Limited's Equity Buyback announced on May 6, 2023, has closed with 30,000,000 shares, representing 13.38% for INR 810 million. CI
20/12 Capnest Health Care Private Limited entered into Business Transfer agreement to acquire Empty Hard Gelatin Capsule unit at Bhatoli from Nectar Lifesciences Limited for approximately INR 200 million. CI
03/12 Nectar Lifesciences approves buyback of shares valued at 810 million rupees RE
03/12 Nectar Lifesciences Limited Appoints Sushil Kapoor as Additional Director and Whole-Time Director, Effective December 4, 2025 CI
03/12 Nectar Lifesciences Limited announces an Equity Buyback for 30,000,000 shares, representing 13.38% for INR 810 million. CI
03/12 Nectar Lifesciences Limited authorizes a Buyback Plan. CI
1 day-1.04%
1 week+2.74%
Current month-0.76%
1 month-10.64%
3 months-13.79%
6 months-23.41%
Current year-45.90%
1 week 10
Extreme 10
10.97
1 month 9.98
Extreme 9.98
11.7
Current year 9.3
Extreme 9.3
20.9
1 year 9.3
Extreme 9.3
22.4
3 years 9.3
Extreme 9.3
56.5
5 years 9.3
Extreme 9.3
56.5
10 years 7.1
Extreme 7.1
56.5
Manager TitleAgeSince
Director of Finance/CFO 68 14/11/2022
Compliance Officer - 01/04/2025
Director TitleAgeSince
Chairman 66 27/06/1995
Director/Board Member 69 11/02/2019
Director/Board Member 75 21/09/2021
Date Insider Type Main position Quantity % Market Cap.
19/12/24 Buy 4,00,000 0.1784%
Change 5-day change 1-year change 3-year change Capi.($)
-1.04%+2.74%-28.91%-57.58% 2.17Cr
+0.57%-1.95%+19.54%+71.30% 4.9TCr
+3.09%+5.78%+64.08%+134.31% 3.94TCr
+1.25%+0.18%-1.52%+22.09% 1.24TCr
-1.17%-1.31%+15.39%+70.53% 1.18TCr
+1.53%-0.38%+30.75%+134.53% 914.14Cr
-0.25%+3.25%+15.49%+35.50% 704.69Cr
+1.61%-6.16%+38.63%-12.74% 686.21Cr
+0.49%+0.37%+10.59%+182.50% 670.43Cr
-1.46%+2.33%-30.59%+14.13% 567.22Cr
Average +0.46%-0.04%+13.34%+59.46% 1.48TCr
Weighted average by Cap. +1.15%-0.40%+28.35%+85.01%

Financials

2024 2025
Net sales 1.68TCr 18Cr 15Cr 14Cr 13Cr 25Cr 25Cr 168.11Cr 66Cr 841.67Cr 66Cr 65Cr 2.8TCr 1.67TCr 18Cr 15Cr 14Cr 13Cr 25Cr 25Cr 166.7Cr 65Cr 834.57Cr 66Cr 64Cr 2.78TCr
Net income 5Cr 5L 5L 4L 4L 7L 7L 49.85L 19.56L 2.5Cr 19.69L 19.26L 8.31Cr -113.68Cr -1.19Cr -1.04Cr -96.97L -88.71L -1.67Cr -1.7Cr -11Cr -4.45Cr -57Cr -4.48Cr -4.38Cr -189.05Cr
Net Debt 615.24Cr 6.46Cr 5.6Cr 5.25Cr 4.8Cr 9.06Cr 9.18Cr 61Cr 24Cr 307.39Cr 24Cr 24Cr 1.02TCr 562.27Cr 5.9Cr 5.12Cr 4.8Cr 4.39Cr 8.28Cr 8.39Cr 56Cr 22Cr 280.93Cr 22Cr 22Cr 935.05Cr
Logo Nectar Lifesciences Limited
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Employees
1,786
Date Price Change Volume
06/26/06 10.50 -1.04% 1,11,259
05/26/05 ₹10.61 +0.76% 73,504
04/26/04 ₹10.53 -1.77% 2,09,897
03/26/03 ₹10.72 +1.32% 95,867
31/26/31 ₹10.58 +3.93% 1,72,613
  1. Stock Market
  2. Stocks
  3. NECLIFE Stock